查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863279

病理学人工智慧市场按产品类型、应用、最终用户和部署模式划分－全球预测（2025-2032年）

Artificial Intelligence in Pathology Market by Product Type, Application, End User, Deployment Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，病理学领域的人工智慧市场规模将达到 3.1613 亿美元，复合年增长率为 15.24%。

主要市场统计数据
基准年 2024 1.0158亿美元
预计年份：2025年 1.1652亿美元
预测年份：2032年 3.1613亿美元
复合年增长率 (%) 15.24%

这本引人入胜且权威的介绍概述了人工智慧技术如何重新定义现代医疗保健系统中的诊断病理工作流程、临床决策支援和检查室操作。

人工智慧正在改变病理学，使其从主要依赖模拟和显微镜的领域转变数位化、数据丰富的领域，从而补充人类的专业知识并简化检查室操作。影像分析、模式识别和预测建模技术的进步，催生了新的诊断工作流程，提高了可重复性，缩短了处理时间，并提取了肉眼无法看到的具有临床意义的讯号。因此，病理学正从说明形态学发展到量化的、可辅助决策的输出，并与电子健康记录和多学科诊疗路径整合。

透过数位化流程、演算法分流、监管成熟和伙伴关係主导的创新策略来变革病理学的关键转折点进行简要分析

病理学领域正经历多重变革，这些变革正在改变诊断服务的提供、检验和商业化方式。首先，临床工作流程正从分段式的、以切片为基础的流程转向整合式数位流程，集中进行影像撷取、标註和分析。这项变革降低了变异性，实现了分散式的第二意见，并透过利用演算法预筛检和优先排序提高了病例处理速度。因此，病理学家花费在复杂解读任务和临床讨论上的时间比例显着高于常规检测。

对2025年美国关税趋势对人工智慧病理技术采购成本、供应链和实施策略的影响进行严格评估

预计2025年实施的关税将对人工智慧病理解决方案的采用和商业化产生多方面的影响。其中一个直接影响通路是资本设备和硬体投入。进口影像系统和专用扫描仪关税的提高将增加医院和实验室的购买成本，促使采购部门重新评估整体拥有成本。这将导致他们优先考虑更长的生命週期管理或国内采购。供应商可能会透过增加本地组装、重新设计产品物料清单以减少对高关税部件的依赖以及转向允许区域定制的模组化架构来应对。

一种主导细分市场的全面观点，将产品类型、用例、最终用户需求和部署模式与实际的采用和整合方案进行绘製。

市场区隔为理解影响病理学人工智慧需求的各种临床和商业性需求提供了一个实用的框架。按产品类型划分，市场分为「服务」与「解决方案」。服务包括专业服务和培训支持，因为成功的人工智慧实施需要为病理学家和技术人员提供咨询、整合和持续教育。解决方案分为硬体和软体，硬体包括成像扫描器和计算设备。软体进一步细分为数据分析软体、全切片成像系统功能以及用于协调病例流转和报告的工作流程管理软体。

区域洞察：美洲、欧洲、中东、非洲和亚太地区在采用驱动因素、法规结构和商业模式方面的差异，以及这些差异如何说明采用策略。

区域趋势正在影响三大主要区域（美洲、欧洲、中东和非洲以及亚太地区）的技术应用、监管预期和伙伴关係模式。在美洲，对高通量、精准专家评审和临床检测支援的需求正在加速整合医疗系统和大型实验室对数位病理学和人工智慧的采用。法规环境强调临床疗效和资料隐私，而商业模式通常将资本投资与以金额为准的服务协议结合。因此，供应商正在优先考虑互通性和可靠的证据生成，以满足不同机构的需求。

企业层面的关键发现凸显了专业供应商、硬体製造商、云端服务供应商和临床合作伙伴在病理学人工智慧领域塑造竞争优势和成功部署方面所发挥的作用。

人工智慧病理诊断领域的竞争格局复杂，既有专业软体供应商，也有影像硬体製造商、系统整合商、云端服务供应商以及学术和临床联盟。专业软体供应商通常强调演算法效能、临床检验研究以及与实验室资讯系统的无缝集成，以此作为差异化优势。影像硬体製造商则在扫描器吞吐量、影像保真度和与全切片成像标准的兼容性方面展开竞争，而係统整合商则专注于端到端实作、服务等级协定以及检查室工作流程最佳化。

为临床领导者和供应商提供切实可行的优先建议，以加速人工智慧病理诊断解决方案的检验应用、提升医护人员的技能水平并实现稳健的商业化。

产业领导者应以清晰的分阶段策略来推进病理学领域的人工智慧应用，以平衡临床检验、互通性和营运准备。首先，应优先发展临床伙伴关係，以进行前瞻性检验研究并将其整合到现有诊断流程中。这些研究应旨在证明人工智慧在诊断准确性、週转时间和患者管理方面的附加价值。其次，应采用模组化架构，将影像撷取和分析分离，使机构能够在现有硬体上试用软体功能，同时保持根据需要升级扫描器或将运算迁移到云端的灵活性。

透明的混合方法调查方法结合了临床访谈、实施案例研究和技术评估，检验实际实施结果。

这些研究结果基于混合方法，整合了质性访谈、临床案例研究和系统性技术评估。主要研究包括与执业病理学家、检查室主任、IT架构师和行业高管进行深入访谈，以了解实际实施过程中遇到的挑战、采购决策驱动因素以及临床检验预期。来自实施点的案例研究揭示了试验计画中发现的通用整合模式、变革管理策略以及可衡量的营运改善。

该策略结论重点强调了将人工智慧的潜力转化为病理学中检验的临床工作流程、营运效率和以患者为中心的可持续结果的实际步骤。

病理学中的人工智慧不再只是实验室辅助工具，而是正在成为现代诊断服务不可或缺的一部分，它能够提高诊断准确性、加快工作流程，并在临床诊疗和检查中创造新的提案。全切片影像、云端分析和经过严格检验的预测模型相结合，为病理学开闢了一条拓展临床应用范围至预后和治疗方案製定的途径，同时还能确保病患安全和资料管治的严格标准。然而，要充分发挥这一潜力，需要的不仅是优秀的演算法；还需要与检查室工作流程进行周密奖励、持续的临床检验以及能够协调相关人员方利益的适应性经营模式。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将可解释人工智慧技术整合到病理演算法中，以提高临床医生的信心并促进监管合规性。
  • 利用人工智慧驱动的多重免疫组化分析量化肿瘤微环境生物标记物，以实现个人化癌症治疗
  • 技术供应商与病理检查室建立策略合作伙伴关係，以实现人工智慧驱动的诊断成像解决方案的商业化。
  • 建立联邦学习框架，利用多样化的病患资料集，安全地进行病理学人工智慧模型的多机构训练
  • 订阅式软体即服务 (SaaS) AI 工具的出现，正在使中小检查室也能进行先进的病理分析。
  • 引入即时人工智慧全切片成像扫描仪，提高了术中会诊和数位冰冻切片诊断的效率。
  • 开发用于跨不同患者群体进行安全、多机构病理学人工智慧模型训练的联邦学习平台
  • 人工智慧解决方案提供者与临床病理检查室建立策略合作伙伴关係，拓展诊断成像商业化进程。
  • 推出基于订阅的SaaS平台，为区域性和中型检查室提供先进的AI病理分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 病理学人工智慧市场（按产品类型划分）

  • 服务
    • 专业服务
    • 培训和支持
  • 解决方案
    • 硬体
    • 软体
      • 数据分析软体
      • 全玻片成像系统
      • 工作流程管理软体

9. 病理学领域人工智慧市场（按应用划分）

  • 计算病理学
  • 数位病理学
    • 远距病理诊断
    • 全切片成像
  • 预测分析
    • 预后模型
    • 风险预测
  • 工作流程优化
    • 病例分诊
    • 资源分配

第十章 病理学人工智慧市场（按最终用户划分）

  • 诊断实验室
    • 医院检查室
    • 参考检验机构
  • 医院诊所
    • 大型医院
    • 中小型医院
  • 製药和生物技术公司
    • 生技Start-Ups
    • 大型製药企业
  • 研究所
    • 学术研究中心
    • 私人考试机构

第十一章 病理学人工智慧市场部署模式

  • 云
    • 私有云端
    • 公共云端
  • 本地部署

第十二章 病理学人工智慧市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 病理学人工智慧市场（按群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国病理学人工智慧市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • PathAI, Inc.
    • Indica Labs, Inc.
    • Inspirata, Inc.
    • aetherAI
    • Aiforia Technologies Oyj
    • Akoya Biosciences, Inc.
    • Danaher Corporation
    • Deep Bio, Inc.
    • Evident Corporation
    • F. Hoffmann-La Roche Ltd.
    • Ibex Medical Analytics Ltd.
    • Koninklijke Philips NV
    • LUMEA, Inc.
    • MindPeak GmbH
    • Nucleai Inc.
    • OptraSCAN Inc.
    • Paige.AI, Inc.
    • Proscia Inc.
    • Siemens Healthineers AG
    • Techcyte, Inc.
    • Tempus Labs, Inc.
    • Tribun Health
    • Visikol, Inc. by CELLINK
    • Visiopharm A/S
Product Code: MRR-1730A405FA4B

The Artificial Intelligence in Pathology Market is projected to grow by USD 316.13 million at a CAGR of 15.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 101.58 million
Estimated Year [2025] USD 116.52 million
Forecast Year [2032] USD 316.13 million
CAGR (%) 15.24%

An engaging and authoritative introduction framing how AI technologies are redefining diagnostic pathology workflows, clinical decision support, and laboratory operations for modern healthcare systems

Artificial intelligence is transforming pathology from a largely analogue, microscope-driven specialty into a digitized, data-rich discipline that augments human expertise and streamlines laboratory operations. Advances in image analysis, pattern recognition, and predictive modeling are enabling new diagnostic workflows that improve reproducibility, reduce turnaround time, and surface clinically relevant signals that might be imperceptible to the human eye. As a result, pathology is evolving from descriptive morphology toward quantified, decision-support enabled outputs that integrate with electronic health records and multidisciplinary care pathways.

This transformation reflects convergence across several technical trends: high-resolution whole slide imaging, cloud-enabled compute resources, robust data annotation practices, and regulatory frameworks that increasingly recognize the clinical value of validated algorithms. Consequently, pathology teams are evaluating AI not as a single tool but as an ecosystem of interoperable components that includes hardware, data pipelines, software analytics, and integrated workflows. For leaders, this means that adoption decisions hinge as much on change management, clinical validation, and interoperability as they do on algorithm performance metrics. As institutions pursue digitization and AI-enabled services, the emphasis shifts to measurable clinical outcomes, operational efficiency, and scalable deployment models that align with institutional risk tolerance and reimbursement pathways.

A concise analysis of the transformative shifts reshaping pathology through digital pipelines, algorithmic triage, regulatory maturation, and partnership-driven innovation strategies

The landscape of pathology is undergoing several transformative shifts that collectively reconfigure how diagnostic services are delivered, validated, and commercialized. First, clinical workflows are migrating from fragmented slide-based processes toward integrated digital pipelines that centralize image acquisition, annotation, and analysis. This shift reduces variability, enables distributed second opinions, and accelerates case throughput by leveraging algorithmic pre-screening and prioritization. As a result, pathologists increasingly spend proportionally more time on complex interpretive tasks and clinical discussions rather than routine screening.

Second, the economics of diagnostic services are changing as AI-enabled capabilities create new value levers. Predictive analytics and prognostic models facilitate personalized therapy selection and clinical trial matching, thereby extending pathology's role into treatment planning and translational research. Third, regulatory and reimbursement landscapes are maturing, with authorities placing greater emphasis on clinical validation, post-market surveillance, and explainability. This strengthens deployment confidence but also raises the bar for evidence generation. Fourth, partnerships between technology vendors, healthcare providers, and research institutions are becoming central to innovation, driving co-development models that integrate clinical expertise early in product design. Ultimately, these shifts create a more distributed, interoperable, and clinically integrated pathology ecosystem focused on measurable improvements in diagnostic accuracy, patient outcomes, and laboratory efficiency.

A rigorous assessment of how 2025 United States tariff dynamics can reshape procurement costs, supply chains, and deployment strategies for AI-enabled pathology technologies

Anticipated tariff measures in the United States in 2025 present a multi-dimensional influence on the adoption and commercialization of AI-enabled pathology solutions. One immediate channel of impact is on capital equipment and hardware inputs. Increased duties on imported imaging systems and specialty scanners elevate acquisition costs for hospitals and reference laboratories, prompting procurement teams to re-evaluate total cost of ownership and prioritize either prolonged lifecycle management or domestic sourcing. In turn, suppliers may respond by localizing assembly, redesigning product BOMs to reduce exposure to tariffed components, or shifting to more modular architectures that permit regional customization.

Another consequential effect pertains to supply chain resilience and inventory strategies. Faced with tariff uncertainty, organizations tend to increase buffer stocks, lengthen procurement cycles, and diversify supplier bases, which can delay deployment timelines for digitization initiatives. On the software front, cloud-delivered analytics experience less direct tariff pressure, but indirect effects arise when cloud solutions rely on regulated or tariffed hardware for edge acquisition. Consequently, system integrators will emphasize hybrid deployment architectures that decouple analysis from acquisition and favor software licensing models that mitigate upfront capital exposure.

From an innovation and commercial strategy perspective, tariffs can accelerate regional competitive dynamics by incentivizing local entrants and manufacturing consolidation. Companies with established domestic manufacturing or strong local partnerships gain relative advantage, while export-oriented vendors must adapt pricing or pursue nearshoring. Finally, clinical adoption decisions reflect not only cost but also risk; higher procurement costs can delay investments in clinical validation studies and real-world evidence programs. Therefore, leaders should anticipate tariff-driven shifts in procurement behavior, supply chain design, pricing strategies, and partnership models, and proactively design deployment roadmaps that preserve project momentum despite external trade pressures.

A comprehensive segmentation-driven perspective that maps product types, application priorities, end-user requirements, and deployment modes to practical adoption and integration choices

Segmentation provides a practical framework for understanding how different clinical and commercial needs shape demand for AI in pathology. Under product type, the market divides into Services and Solutions. Services encompass Professional Services and Training & Support, recognizing that successful AI deployments require consulting, integration, and sustained education for pathologists and laboratory staff. Solutions split into Hardware and Software, where Hardware includes imaging scanners and compute appliances and Software fragments further into Data Analysis Software, Whole Slide Imaging System capabilities, and Workflow Management Software that orchestrates case routing and reporting.

Application-level segmentation highlights both diagnostic and operational use cases. Computational Pathology focuses on algorithmic interpretation and feature extraction, while Digital Pathology covers telepathology and whole slide imaging workflows that enable remote review and distributed case sharing. Predictive Analytics emphasizes models such as Prognostic Models and Risk Prediction that extend pathology's role into outcome forecasting. Workflow Optimization captures operational use cases like Case Triage and Resource Allocation that improve lab throughput and prioritize urgent cases.

End-user segmentation underscores where value realization occurs. Diagnostic Laboratories are differentiated between Hospital-Based Labs and Reference Laboratories, each with distinct volume patterns and integration needs. Hospitals & Clinics span Large Hospitals and Small & Mid-Size Hospitals, reflecting differences in IT maturity and procurement cycles. Pharma & Biotech include Biotech Startups and Large Pharma, which leverage pathology AI for biomarker discovery and companion diagnostics, while Research Institutes cover Academic Research Centers and Private Labs that drive translational validation and algorithm training. Finally, deployment mode differentiates Cloud and On-Premise approaches, with Cloud further divided into Private Cloud and Public Cloud options that balance scalability, latency, and data governance preferences. This multi-dimensional segmentation clarifies where technical capabilities, commercialization models, and clinical validation priorities must align to achieve meaningful outcomes.

Actionable regional insights that explain how adoption drivers, regulatory frameworks, and commercial models differ across the Americas, EMEA, and Asia-Pacific and what that means for deployment strategies

Regional dynamics influence technology adoption, regulatory expectations, and partnership models across three principal geographies: the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, digital pathology and AI deployments accelerate in integrated health systems and large reference laboratories, driven by demand for higher throughput, centralized specialist review, and clinical trial support. The regulatory environment emphasizes clinical validation and data privacy, while commercial models often combine capital investment with value-based service agreements. Consequently, vendors tend to prioritize interoperability and robust evidence generation to satisfy diverse institutional requirements.

In Europe, Middle East & Africa, adoption patterns vary significantly by country and healthcare setting, with advanced digital initiatives concentrated in metropolitan centers and academic hubs. Regulatory frameworks emphasize patient data protection and clinical performance, and public procurement processes can shape vendor selection through long lead cycles and tender-based contracts. Meanwhile, the Asia-Pacific region demonstrates rapid uptake in metropolitan hospitals and private labs, supported by investment in digital infrastructure, domestic technology suppliers, and a high appetite for performance-enhancing tools. Across these regions, differences in reimbursement models, local manufacturing capabilities, and regulatory pathways create both challenges and opportunities. Hence regional strategies must adapt product architectures, pricing models, and partnership structures to reconcile local clinical priorities with global development plans.

Key company-level insights revealing how specialized vendors, hardware makers, cloud providers, and clinical partnerships shape competitive advantage and deployment success in pathology AI

Competitive dynamics in AI-enabled pathology reflect a mix of specialized software vendors, imaging hardware manufacturers, systems integrators, cloud service providers, and academic-clinical consortia. Specialized software vendors tend to differentiate on algorithmic performance, clinical validation studies, and seamless integration with laboratory information systems. Imaging hardware manufacturers compete on scanner throughput, image fidelity, and compatibility with whole slide imaging standards, while systems integrators emphasize end-to-end implementation, service-level agreements, and laboratory workflow optimization.

Cloud service providers and managed service operators offer scalable compute and regulatory-compliant hosting options that reduce capital barriers for institutions, and partnerships between technology vendors and clinical centers accelerate real-world validation. Additionally, a growing number of consortium-driven initiatives and startup spinouts are driving niche innovations in areas such as stain normalization, multiplexed tissue analysis, and model explainability. From a strategic standpoint, companies that combine rigorous clinical validation, clear regulatory pathways, and partnership-oriented commercial models gain sustainable advantage. Mergers and acquisitions remain a common route for incumbents to acquire capabilities rapidly, while thoughtful alliances between vendors and clinical networks enable faster deployment and evidence generation. Ultimately, the competitive landscape rewards organizations that balance technical excellence with operational support and a transparent roadmap to clinical impact.

Practical and prioritized recommendations for clinical leaders and vendors to accelerate validated deployment, workforce readiness, and resilient commercialization of AI-powered pathology solutions

Industry leaders should approach AI in pathology with a clear, phased strategy that balances clinical validation, interoperability, and operational readiness. First, prioritize clinical partnerships that enable prospective validation studies and integration into existing diagnostic pathways; these studies should be designed to demonstrate incremental value in diagnostic accuracy, turnaround time, or patient management. Second, adopt modular architectures that decouple image acquisition from analytics so organizations can pilot software capabilities on existing hardware while preserving flexibility to upgrade scanners or migrate compute to the cloud as needed.

Third, invest in workforce readiness through targeted training and continuous education programs that cover model limitations, interpretability, and workflow changes; clinicians who understand how AI augments their decisions accelerate adoption and mitigate unintended consequences. Fourth, align procurement and contracting with total cost of ownership thinking by incorporating software-as-a-service options, performance guarantees, and shared-risk arrangements that reduce upfront capital exposure. Fifth, develop robust data governance and validation frameworks that document training cohorts, performance across demographic groups, and post-deployment monitoring plans. Finally, cultivate diverse partnerships with local manufacturing, academic centers, and clinical networks to increase resilience against supply chain disruptions and regulatory variability. Taken together, these actions position leaders to translate technological potential into reliable clinical and operational outcomes.

A transparent, mixed-method research methodology combining primary clinical interviews, implementation case studies, and technical assessments to validate practical adoption insights

The research underpinning these insights employed a mixed-methods approach that integrates primary qualitative interviews, clinical case studies, and systematic technology assessment. Primary research included in-depth conversations with practicing pathologists, laboratory directors, IT architects, and industry executives to capture real-world implementation challenges, procurement decision drivers, and clinical validation expectations. Case studies drawn from implementation sites illustrate common integration patterns, change management strategies, and measurable operational improvements observed during pilot programs.

Secondary analysis combined peer-reviewed literature, regulatory guidance documents, and publicly available technical white papers to map algorithmic performance characteristics, data governance expectations, and interoperability standards. Technology assessment focused on image acquisition fidelity, algorithm robustness across staining and scanner variability, and workflow orchestration capabilities. Data triangulation validated qualitative findings against technical specifications and regulatory milestones. Throughout, emphasis remained on replicable methods, transparency in evidence sources, and clear delineation between observed practices and emerging trends, ensuring that recommendations are actionable and grounded in clinical realities.

A strategic conclusion emphasizing pragmatic steps to convert AI promise into validated clinical workflows, operational gains, and sustainable patient-centric outcomes in pathology

AI in pathology is no longer an experimental adjunct; it is becoming an integral element of modern diagnostic services that can enhance accuracy, accelerate workflows, and enable new value propositions across clinical care and research. The combination of whole slide imaging, cloud-enabled analytics, and carefully validated predictive models creates a pathway for pathology to expand its clinical remit into prognostication and treatment planning while maintaining rigorous standards for patient safety and data governance. Nevertheless, realizing this potential requires more than superior algorithms; it calls for thoughtful integration with laboratory workflows, sustained clinical validation, and adaptive commercial models that align incentives across stakeholders.

As organizations embrace digitization, priorities should include investing in robust data infrastructure, cultivating clinician buy-in through education and co-development, and designing deployment roadmaps that can withstand supply chain and regulatory variability. By focusing on measurable outcomes and flexible architectures, pathology leaders can convert technological promise into operational value that supports better patient care, faster decision making, and more efficient use of scarce specialist resources. The path forward is iterative: pilot, validate, scale, and monitor-each stage informed by clinical evidence and operational metrics that demonstrate real-world impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of explainable AI techniques within pathology algorithms to boost clinician trust and facilitate regulatory compliance
  • 5.2. Adoption of AI-driven multiplex immunohistochemistry analysis to quantify tumor microenvironment biomarkers for personalized cancer therapies
  • 5.3. Strategic partnerships between technology vendors and pathology laboratories to commercialize AI-driven diagnostic imaging solutions
  • 5.4. Establishment of federated learning frameworks for secure multi-institutional training of pathology AI models on diverse patient datasets
  • 5.5. Introduction of regulatory-approved deep learning algorithms improving prognostic accuracy and reducing diagnostic variability in hematopathology
  • 5.6. Emergence of subscription-based software-as-a-service AI tools democratizing advanced pathology analytics for small and mid-sized laboratories
  • 5.7. Deployment of real-time AI-enabled whole slide image scanners to streamline intraoperative consultations and digital frozen section reviews
  • 5.8. Development of federated learning infrastructures enabling secure multi-center pathology AI model training on diverse patient cohorts
  • 5.9. Strategic alliances between AI solution providers and clinical pathology labs to scale diagnostic imaging commercialization
  • 5.10. Launch of subscription-based SaaS platforms bringing advanced AI pathology analytics to community and mid-size laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Pathology Market, by Product Type

  • 8.1. Services
    • 8.1.1. Professional Services
    • 8.1.2. Training & Support
  • 8.2. Solutions
    • 8.2.1. Hardware
    • 8.2.2. Software
      • 8.2.2.1. Data Analysis Software
      • 8.2.2.2. Whole Slide Imaging System
      • 8.2.2.3. Workflow Management Software

9. Artificial Intelligence in Pathology Market, by Application

  • 9.1. Computational Pathology
  • 9.2. Digital Pathology
    • 9.2.1. Telepathology
    • 9.2.2. Whole Slide Imaging
  • 9.3. Predictive Analytics
    • 9.3.1. Prognostic Models
    • 9.3.2. Risk Prediction
  • 9.4. Workflow Optimization
    • 9.4.1. Case Triage
    • 9.4.2. Resource Allocation

10. Artificial Intelligence in Pathology Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital-Based Labs
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals & Clinics
    • 10.2.1. Large Hospitals
    • 10.2.2. Small & Mid-Size Hospitals
  • 10.3. Pharma & Biotech
    • 10.3.1. Biotech Startups
    • 10.3.2. Large Pharma
  • 10.4. Research Institutes
    • 10.4.1. Academic Research Centers
    • 10.4.2. Private Labs

11. Artificial Intelligence in Pathology Market, by Deployment Mode

  • 11.1. Cloud
    • 11.1.1. Private Cloud
    • 11.1.2. Public Cloud
  • 11.2. On-Premise

12. Artificial Intelligence in Pathology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Intelligence in Pathology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Intelligence in Pathology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. PathAI, Inc.
    • 15.3.2. Indica Labs, Inc.
    • 15.3.3. Inspirata, Inc.
    • 15.3.4. aetherAI
    • 15.3.5. Aiforia Technologies Oyj
    • 15.3.6. Akoya Biosciences, Inc.
    • 15.3.7. Danaher Corporation
    • 15.3.8. Deep Bio, Inc.
    • 15.3.9. Evident Corporation
    • 15.3.10. F. Hoffmann-La Roche Ltd.
    • 15.3.11. Ibex Medical Analytics Ltd.
    • 15.3.12. Koninklijke Philips N.V.
    • 15.3.13. LUMEA, Inc.
    • 15.3.14. MindPeak GmbH
    • 15.3.15. Nucleai Inc.
    • 15.3.16. OptraSCAN Inc.
    • 15.3.17. Paige.AI, Inc.
    • 15.3.18. Proscia Inc.
    • 15.3.19. Siemens Healthineers AG
    • 15.3.20. Techcyte, Inc.
    • 15.3.21. Tempus Labs, Inc.
    • 15.3.22. Tribun Health
    • 15.3.23. Visikol, Inc. by CELLINK
    • 15.3.24. Visiopharm A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD M